Catalyst

Slingshot members are tracking this event:

Bristol-Myers Squibb (BMY) Announces Positive Opinion from European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on Opdivo for Classical Hodgkin Lymphoma

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BMY

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 14, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Positive Opinion, European Medicines Agency, Ema, Chmp, Adult Patients, Relapsed, Refractory, Classical Hodgkin Lymphoma, Autologous Stem Cell Transplant, Brentuximab Vedotin